← Back to all trials
Not Yet Recruiting
NCT07654257
Single FrAction Interstitial BreaSt BracHytherApy
Conditions: Breast Cancer
Sex: Female
Ages: 40 Years – 85 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 134
Sponsor: Virginia Commonwealth University
Location: Virginia Commonwealth University Richmond Virginia
Summary
This phase 2, single arm prospective study has been designed to determine the safety of delivering accelerated partial breast irradiation (APBI) with a multicatheter interstitial implant in a single fraction over 1 day. This is a method of delivering radiation therapy directly into or close to a tumor.
Eligibility Criteria
Inclusion Criteria:
* Female
* New diagnosis of DCIS and/or invasive breast carcinoma per histologic evaluation
* Age 40-85 at diagnosis
* Previous lumpectomy with surgical margins histologically free of invasive tumor and DCIS as determined by the pathologist
* T stage of Tis, T1, or T2
* T2 tumors must be ≤3 cm in maximum diameter
* If the tumor is HER2-positive, the patient is planning to receive or has already received HER2-directed therapy
* For patients with invasive breast cancer, an axillary staging procedure must be performed (either sentinel node biopsy alone or axillary dissection \[with a minimum of 6 axillary nodes removed\]) and the axillary node(s) must be pathologically negative Note: N0(i+) is not an exclusion criterion
Note: Patients meeting all of the following criteria are not required to undergo the axillary staging procedure:
* ≥70 years of age
* ER+, PR+/-, HER2-
* Grade 1-2 breast cancer
* Tumor ≤2 cm in size
Note: If patients meet all the following criteria, the decision to avoid sentinel lymph node biopsy can be at the discretion of the breast surgeon:
* 50-69 years of age
* Grade 1-2 breast cancer
* Clinically negative axilla by ultrasound and/or MRI
* ER+, PR+, HER2-
* Tumor ≤2 cm in size
* Agrees to comply with aromatase inhibitor recommendation
* Ability to begin brachytherapy within 12 weeks following lumpectomy, re- excision of margins, or completion of chemotherapy
* Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
* Pregnant or breastfeeding
* Active collagen-vascular disease
* Paget's disease of the breast
* Any prior history of DCIS or invasive breast cancer prior to the current diagnosis
* Any prior history of breast RT or thoracic RT for any condition
* Multicentric carcinoma (DCIS or invasive)
* Synchronous bilateral invasive or non-invasive breast cancer
* Surgical margins that cannot be microscopically assessed or that are positive
* Treatment with neoadjuvant chemotherapy
* Excision cavity that cannot be clearly delineated or is not amenable to implant per the treating investigator
* Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements
Source: ClinicalTrials.gov (NCT07654257). StuddyBuddy aggregates publicly available trial information.